Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Capital Expenditures (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Capital Expenditures for 4 consecutive years, with $9999.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 27.4% to $9999.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $60000.0, a 62.4% decrease, with the full-year FY2024 number at $103773.0, up 80.09% from a year prior.
  • Capital Expenditures was $9999.0 for Q3 2025 at 60 Degrees Pharmaceuticals, down from $47323.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $89274.0 in Q2 2024 to a low of -$13596.0 in Q3 2023.
  • A 4-year average of $20962.7 and a median of $11063.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 858.14% in 2023, then soared 636.16% in 2024.
  • 60 Degrees Pharmaceuticals' Capital Expenditures stood at $31575.0 in 2022, then skyrocketed by 76.72% to $55800.0 in 2023, then crashed by 75.32% to $13773.0 in 2024, then decreased by 27.4% to $9999.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Capital Expenditures are $9999.0 (Q3 2025), $47323.0 (Q2 2025), and $2678.0 (Q1 2025).